TERT promoter–mutated thyroid carcinomas: prognostic and histologic insights according to the WHO 2022 classification
Histopathology · 2026-08 · 89 (2) · 262-277
DOI: 10.1111/his.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 17.04.2026. Verfasst von Seung Eun Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Telomerase. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Aims
TERT promoter mutations are late molecular events associated with tumour dedifferentiation and aggressive behaviour in thyroid carcinomas (TCs). Although certain adverse histologic features, particularly tall cell morphology, are enriched in TERT promoter–mutated papillary thyroid carcinoma (PTC), their independent prognostic significance within the American Thyroid Association (ATA) high‐risk group remains uncertain. This study aimed to assess its prognostic relevance and characterize the histologic spectrum of TERT promoter–mutated TCs, including differentiated high‐grade thyroid carcinoma (DHGTC), to refine risk stratification. Methods and results We retrospectively analysed 151 TCs harbouring TERT promoter mutations, reclassified according to the WHO 2022 classification, which includes newly defined DHGTC. The low frequency of TERT promoter mutations in PTC (2.4%) likely reflects the reclassification of cases previously diagnosed as PTC to DHGTC. Tall cell morphology remained strongly associated with TERT promoter mutations but did not confer additional prognostic significance within this ATA high‐risk group. Furthermore, applying the stricter WHO criteria for TC‐PTC (≥3× height criteria) did not enhance risk stratification. Importantly, histologic features indicative of tumour progression, including loss of polarity/cohesiveness and early necrotic change, were frequently observed and significantly associated with aggressive clinicopathologic features. Accordingly, tumours exhibiting these features may not only reflect progression toward high‐grade disease but also serve as surrogate histologic indicators of underlying TERT promoter mutations.
Conclusions
Our study provides valuable insights into TERT promoter–mutated TCs, broadening their recognized morphologic spectrum and highlighting the importance of incorporating such features into routine evaluation to improve risk stratification and better identify aggressive tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
ORCID-Profile: Seung Eun Lee, Bogyeong Han, Jung-Sun Kim, Young Lyun Oh
Zitieren
APA
Lee, S. E., Han, B., Kim, J. S., & Oh, Y. L. (2026). TERT promoter–mutated thyroid carcinomas: prognostic and histologic insights according to the WHO 2022 classification. Histopathology, 89(2), 262-277. https://doi.org/10.1111/his.70152
Vancouver
Lee SE, Han B, Kim JS, Oh YL. TERT promoter–mutated thyroid carcinomas: prognostic and histologic insights according to the WHO 2022 classification. Histopathology. 2026;89(2):262-277. doi:10.1111/his.70152
BibTeX
@article{Lee2026,
author = {Lee, Seung Eun and Han, Bogyeong and Kim, Jung-Sun and Oh, Young Lyun},
title = {TERT promoter–mutated thyroid carcinomas: prognostic and histologic insights according to the WHO 2022 classification},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {2},
pages = {262--277},
doi = {10.1111/his.70152}
}
EUVIMED